NeuroVive Pharmaceutical AB RSI
Quel est le RSI de NeuroVive Pharmaceutical AB?
Le RSI de NeuroVive Pharmaceutical AB est 48.02
Quelle est la définition de RSI?
L'indice de force relative (RSI 14) est un indicateur de dynamique qui compare l'ampleur des gains et des pertes sur une période donnée afin de mesurer la vitesse et l'évolution des mouvements de prix d'un titre.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI des entreprises dans Miscellaneous secteur sur LSE par rapport à NeuroVive Pharmaceutical AB
Que fait NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Entreprises avec rsi similaire à NeuroVive Pharmaceutical AB
- AND International Publishers NV a RSI de 48.01
- AXISCADES Engineering Technologies a RSI de 48.01
- Orchid Island Capital Inc a RSI de 48.01
- Tandy Leather Factory a RSI de 48.01
- Bruker Corp a RSI de 48.01
- Johnson Service Plc a RSI de 48.01
- NeuroVive Pharmaceutical AB a RSI de 48.02
- Douglas Dynamics Inc a RSI de 48.03
- E-Tech Resources a RSI de 48.03
- Silver One Resources a RSI de 48.03
- Eastern Bankshares a RSI de 48.03
- Sastasundar Ventures a RSI de 48.03
- Golden Path Acquisition a RSI de 48.03